WSJ: Sanofi in no rush to close Genzyme deal

The Wall Street Journal has pondered all the signs surrounding the now-quiet buyout discussions between Sanofi and Genzyme and concluded that it may well be months before any definitive deal emerges. Why? Sanofi has a history of taking deliberate steps in its buyout talks and has never been known to rush into anything. And it has some big shareholders that may be willing to hold it back from any acquisition that looks too pricey. As for Genzyme, nothing short of a sweet deal close to one of its price highs is likely to get its executives excited. Bottom line: Stay patient until you hear the next big rumor on this story. News

Suggested Articles

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Although Genfit canned its NASH program last month, it has been plugging away at a blood-based diagnostic for the liver disease.